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PEA-15 Mediates Cytoplasmic Sequestration
of ERK MAP Kinase
biological outputs by phosphorylating nuclear and cyto-
plasmic substrates. Nuclear substrates include tran-
scription factors such as Elk-1, and cytoplasmic sub-
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and Herve´ Chneiweiss1,5,7 tial point of regulation. For example, translocation of
1 INSERM U114 ERK from the cytoplasm to the nucleus is required for
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France as a selectable marker, established that a Ras-activated
MAP kinase pathway suppresses integrin activation in
fibroblasts with consequent alterations in cell adhesion
and cytoskeletal organization (Hughes et al., 1997).Summary
We used expression cloning to identify PEA-15 as a
protein that blocks Ras suppression of integrin activa-The ERK 1/2 MAP kinase pathway controls cell growth
tion without inhibiting ERK activation (Ramos et al.,and survival and modulates integrin function. Here, we
1998). PEA-15 is a multifunctional protein that also pro-report that PEA-15, a protein variably expressed in
tects against TNF-induced apoptosis (Kitsberg et al.,multiple cell types, blocks ERK-dependent transcrip-
tion and proliferation by binding ERKs and preventing 1999) and promotes resistance to insulin in type II diabe-
their localization in the nucleus. PEA-15 contains a tes (Condorelli et al., 1998). It is expressed in a broad
nuclear export sequence required for its capacity to range of tissues and enriched in brain astrocytes. PEA-
anchor ERK in the cytoplasm. Genetic deletion of PEA- 15 can be phosphorylated at two serines by protein
15 results in increased ERK nuclear localization with kinase C (S104) and calcium calmodulin kinase II (S116;
consequent increased cFos transcription and cell pro- Araujo et al., 1993; Kubes et al., 1998; Estelles et al.,
liferation. Thus, PEA-15 can redirect the biological out- 1996). PEA-15 also contains a death effector domain
come of MAP kinase signaling by regulating the sub- (DED), a signature motif in proteins that regulate apo-
cellular localization of ERK MAP kinase.
ptosis (Ashkenazi and Dixit, 1998). Thus, these results
suggested an unexpected connection between the con-
Introduction trol of apoptosis and the regulation of MAP kinase sig-
naling. However, the effect of PEA-15 on known sub-
MAP kinases such as p42/44 extracellular regulated ki- strates of ERK MAP kinases has not been assessed.
nases (ERK), p38/SAPK2’s, and Jun kinases (JNK; Lewis In this study, we have found that the expression of
et al., 1998; Cobb, 1999) play a central role in the activi- PEA-15 in cells blocks the ability of ERK MAP kinase
ties of all eukaryotic organisms. MAP kinases are regu- to phosphorylate the transcription factor, Elk-1, and to
lated through the control of initiation and propagation promote ERK-dependent transcription. In contrast, the
of cascades of kinases. In addition, MAP kinases are protein has no effect on the phosphorylation of cyto-
dephosphorylated and inactivated by multiple phospha- plasmic substrates, stathmin and p90RSK. The effect
tases (Waskiewicz and Cooper, 1995), and the efficiency of PEA-15 on ERK signaling is due to its binding to ERKs
of MAP kinase activation is affected by the assembly of and the inhibition of their accumulation in the nucleus.
components of MAP kinase cascades (Schaeffer and PEA-15 contains a nuclear export sequence that medi-
Weber, 1999) by scaffolding proteins. MAP kinases elicit ates the relocation of ERK to the cytoplasm. Further-
more, genetic deletion of PEA-15 markedly stimulates
5 Correspondence: ramos@biology.rutgers.edu (J.W.R.), herve. ERK-dependent proliferation and gene transcription.
chneiweiss@college-de-france.fr (H.C.) Thus, PEA-15 expression levels control the biological6 Present address: Nelson Biological Laboratories, Rutgers, The
outcomes of the ERK MAP kinase pathway by regulatingState University of New Jersey, Piscataway, New Jersey 08854.
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Figure 1. PEA-15 Prevents ERK Signaling to
Elk-1, but Not to Stathmin
(A) Cell lysates from serum-stimulated cells
transfected with PEA-15 or control vector
alone were Western blotted with anti-phos-
pho-Elk-1 antibody (upper panel) or anti-
Elk-1 antibody (lower panel).
(B) ERK phosphorylates its cytoplasmic sub-
strate stathmin. Lysates from serum-stimu-
lated (serum) or unstimulated (serum)
cells transfected with PEA-15 or control vec-
tor alone were Western blotted with anti-
phosphostathmin (upper panel) or anti-stath-
min antibodies (lower panel).
(C) Elk-1-dependent transcriptional activity
was measured as described in the Experi-
mental Procedures in serum-stimulated and
unstimulated cell lysates transfected with
PEA-15 or control vector. The results shown
are from an experiment done in triplicate and
are representative of more than ten indepen-
dent assays.
(D) Approximately 1 nM of activated (ERK*)
or nonactivated (ERK) ERK was purified from
cytosolic extracts of NIH 3T3 cells and in-
cubated with GST-Elk-1 (307-428) in the
presence of [32P]ATP and increasing concen-
trations of PEA-15. Depicted are autoradio-
graphs indicating the phosphorylation of Elk-1
by ERK* and the failure of PEA-15 to block
phosphorylation.
(E) NIH 3T3 cells stably expressing GFP-PEA-
15 or GFP were cultured for 18 hr in the pres-
ence of 0.2% serum and stimulated with 20%
FCS for the indicated time. ERK phosphoryla-
tion was assessed with anti-phospho-ERK
(upper panel), and total ERK was estimated
with anti-ERK 1/2 (lower panel) antibodies.
1E), as expected (Ramos et al., 1998, 2000). Thus, PEA-Results
15 blocks the capacity of ERK to phosphorylate nuclear
substrates and activate transcription, but does not im-PEA-15 Blocks Phosphorylation of Nuclear
pair the activation or the enzymatic activity of ERK.but Not Cytoplasmic ERK Substrates
We previously identified PEA-15 by its blockade of Ras-
induced suppression of integrin activation. To examine PEA-15 Blocks ERK Translocation to the Nucleus
These studies suggested that PEA-15 might impair ERKthe effects of PEA-15 on other targets of the MAP kinase
pathway, we assessed its effects on the phosphorylation nuclear translocation. To test this possibility, we as-
sessed the nuclear localization of ERK in cells express-of nuclear and cytoplasmic ERK substrates. Expression
of PEA-15 markedly inhibited serum-stimulated phos- ing high levels of PEA-15. The PEA-15 was tagged with
GFP so that its localization could be examined simulta-phorylation of the nuclear substrate, Elk-1 (Figure 1A),
but had no effect on phosphorylation of the cytoplasmic neously with ERK. Immunofluorescence revealed that
ERK was largely confined to the cytosol in PEA-15-substrate, stathmin (Figure 1B) or p90RSK (data not
shown). The inhibition of phosphorylation of nuclear transfected cells. The addition of 20% serum failed to
stimulate nuclear localization (Figure 2A). In cells trans-substrates resulted in abrogation of ERK-stimulated
transcriptional activation of Elk-1 (Figure 1C). Suppres- fected with GFP alone, ERK localization was largely nu-
clear in serum-stimulated cells and predominantly cyto-sion of serum response element-dependent transcrip-
tion was also observed (data not shown). PEA-15 did plasmic in serum-starved cells (Figure 2A). PEA-15 was
restricted to the cytoplasm in the presence or absencenot block ERK kinase activity because addition of exog-
enous PEA-15 to purified, activated ERK failed to block of serum (Figure 2B). In order to confirm and quantify
these immunofluorescence results, subcellular fraction-recombinant Elk-1 phosphorylation in vitro (Figure 1D).
On the contrary, PEA-15 enhanced and prolonged the ation experiments were performed. In serum-stimulated,
PEA-15-transfected cells, less than 22% of ERK 1 andserum-stimulated activation of ERK MAP kinase (Figure
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2 were in the nucleus. In sharp contrast, in control cells,
56% of ERK 1 and 2 were in the nucleus (Figure 2C).
Thus, increased expression of PEA-15 results in im-
paired ERK translocation to the nucleus.
PEA-15, at Physiological Abundance,
Regulates ERK Signaling
As described above, we found that forced expression
of PEA-15 resulted in impaired ERK translocation to the
nucleus. As previously noted, PEA-15 is highly ex-
pressed in astrocytes, cells that are normally quiescent
in vivo. To further assess the role of PEA-15 in ERK
signaling under physiological conditions, we examined
the proliferative response of PEA-15 null and wild-type
astrocytes. The PEA-15 null astrocytes showed a
marked increase in tritiated thymidine incorporation in
0.2% or 10% serum. In the presence of 10% serum,
tritiated thymidine incorporation was approximately
3-fold greater in the null cells as compared to the PEA-
15-expressing cells (Figure 3A). Furthermore, this in-
crease in thymidine incorporation was associated with
an increased serum response element-dependent cFos
transcription (Figure 3B). In addition, lack of PEA-15
led to an increased proliferation rate as reflected by
increases in cell number (Figure 3C). These changes
in proliferative response in the PEA-15 null cells were
associated with an alteration in the nuclear localization
of ERK. Thus, even in the presence of 0.2% serum, ERK
was largely localized to the nucleus in the PEA-15 null
cells. In contrast, in PEA-15-expressing cells, nuclear
localization was only observed in the presence of 20%
serum (Figure 3D). In spite of these differences in nuclear
localization, there was little difference in the extent of
ERK activation in the wild-type and knockout cells in
0.2% or 20% serum (data not shown). To determine
whether these differences between PEA-15 null and
wild-type cells were as a direct consequence of the
loss of PEA-15 expression, we reconstituted the null
astrocytes with PEA-15 and examined ERK localization.
As expected, ERK no longer accumulated in the nucleus
of these cells (Figures 3E and 3F), demonstrating that
reexpression of PEA-15 restored a wild-type phenotype.
Thus, in primary astrocytes, PEA-15 regulates the nu-
clear localization of ERK and, consequently, transcrip-
tion of ERK-dependent targets and cell proliferation.Figure 2. PEA-15 Prevents Serum-Induced ERK Translocation to
the Nucleus
A Nuclear Export Sequence in PEA-15 Is Required(A) NIH 3T3 cells expressing GFP-PEA-15 or GFP alone were cul-
tured for 18 hr in the presence of 0.2% FCS. Subsequently, cells to Regulate ERK Localization
were stimulated by the addition of 20% FCS for 3 hr (serum) or Our experiments suggested that PEA-15 regulated the
maintained in 0.2% FCS (starved). ERK was imaged by confocal nuclear transport of ERK. PEA-15 is localized to the
microscopy of cells stained with anti-ERK. Note the lack of ERK
cytoplasm (Danziger et al., 1995), although its small sizetranslocation in response to serum in the PEA-15-expressing cells.
should allow it to diffuse into the nucleus. Thus, weIdentical results were obtained with two other independent cell lines
assessed the possibility of active nuclear export of PEA-(data not shown). The scale bar represents 10 m.
(B) GFP was imaged by confocal microscopy in NIH 3T3 cells ex- 15. Treatment of fibroblasts with a specific inhibitor of
pressing GFP-PEA-15 or GFP. nuclear export, leptomycin B (Wolff et al., 1997), resulted
(C) CHO cells were transfected with PEA-15 or empty vector. Cells in a rapid accumulation of PEA-15 in the nucleus (Figure
were serum stimulated for 3 hr and cytoplasmic (Cyto) and nuclear
4A). Moreover, this redistribution of PEA-15 was accom-(Nucl) extracts were prepared as previously described (Sperling et
panied by nuclear localization of ERK (Figure 4B). Lepto-al., 1985). The top panel is a Western blot incubated with anti-ERK
mycin B blocks nuclear export of proteins containing a1/2 antibody. The middle panel is a Western blot visualized with
anti-PEA-15 (antibody 3099). The bottom panel shows a Western leucine-rich nuclear export sequence (NES) by pre-
blot visualized with anti-lamin antibodies. Note that lamin is located venting the binding of the NES to the export receptor,
only in the nuclear fraction, as expected. CRM1 (Fornerod et al., 1997; Fukuda et al., 1997; Kudo
et al., 1998). Sequence alignment with the NES of three
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Figure 3. PEA-15 Regulates ERK Localization and Function in Astrocytes
(A) [Methyl-3H]thymidine incorporation is increased in PEA-15 null astrocytes. Wild-type (WT) or PEA-15 null (KO) astrocytes were cultured in
0.2% serum for 24 hr, and then stimulated with 10% FCS (filled bars) or continued in 0.2% serum (open bars), in the presence of [methyl-
3H]thymidine for the last 10 hr. Incorporated [methyl-3H]thymidine was precipitated with 10% trichloroacetic acid and measured in a scintillation
spectrometer. Means  SD of quadruplicate values.
(B) Wild-type (WT) or PEA-15 null (KO) astrocytes were cultured in 0.2% serum for 24 hr and then stimulated with 20% FCS () or continued
in 0.2% serum (). cFos induction was measured by Northern blotting using a radiolabeled probe obtained from human cFos (upper panel).
Equivalent amounts were loaded as assessed by hybridization with a probe for glyceraldehyde-3-phosphate dehydrogenase (GAPDH, lower
panel). Note that in PEA-15 null cells, cFos induction was significantly increased. In three independent experiments, serum-stimulated cFos
induction was 1.7  0.2 (mean  SEM)-fold higher in KO astrocytes than in WT cells.
(C) PEA-15 null astrocytes show a higher proliferation rate in culture. 2  105 wild-type (WT, triangles) or PEA-15 null (KO, circles) astrocytes
were seeded in 35 mm dishes and grown for the indicated time in medium supplemented with 10% FCS. Cells were then trypsinized and
enumerated with a hemocytometer. Shown are means  SD of duplicate values. Results are representative of five independent experiments.
(D) ERK localization in PEA-15 null astrocytes. Wild-type (WT) or PEA-15 null (KO) astrocytes were cultured in 0.2% serum for 24 hr. Subsequently,
they were stimulated with 20% serum for 3 hr (serum) or maintained in 0.2% serum (starved) and then stained for ERK 1. Cells in which the
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Figure 4. PEA-15 Possesses a Nuclear Ex-
port Sequence, which Is Required for ERK
Localization
(A) NIH 3T3 cells expressing GFP-PEA-15 or
GFP were treated with leptomycin B (10 ng/
ml) for the indicated time, and the localization
of the GFP fusion proteins was monitored by
confocal microscopy. Note the rapid localiza-
tion of GFP-PEA-15 to the nucleus following
leptomycin B treatment. This is representa-
tive of five independent experiments giving
similar results. The scale bar represents
20 m.
(B) NIH 3T3 cells expressing GFP-PEA-15
were treated with leptomycin B for 3 hr
(LEPTO) or not (Control), and stained for
ERK. The proteins were imaged by immuno-
fluorescence in confocal microscopy. Note
that ERK nuclear accumulation following lep-
tomycin B treatment paralleled PEA-15 local-
ization to the nucleus. The scale bar repre-
sents 10 m.
(C) Sequence alignment shows that PEA-15
possesses a putative nuclear export signal
(NES). Amino acids 7–17 of PEA-15 were
compared to the NES of MAPK-ERK kinase
1 (MEK1), protein kinase A inhibitor (PKI),
and Rev; critical hydrophobic residues (Hen-
derson and Eleftheriou, 2000) are shaded.
The asterisk indicates the amino acid mu-
tated in (D).
(D) CHO cells were transfected with wild-type
PEA-15 (PEA), the I15A mutant (PEA*), or
empty vector (None). Cytosolic (Cytosol) and
nuclear (Nucleus) extracts were prepared and
Western blotted with anti-PEA-15 (upper
panel) and anti-ERK 1/2 (second panel) anti-
bodies. The extracts were also blotted with
anti-lamins (third panel) and anti-Rho GDI
(lower panel) antibodies to assay the separa-
tion of the nuclear and cytosolic fractions.
Note that in cells transfected with the PEA*
mutant, both PEA-15 and ERK accumulated
in the nucleus.
exported proteins indicated a candidate NES at the N PEA-15 Binds ERK 1 and 2
To gain further insight into the mechanism by whichterminus of PEA-15 (Figure 4C; Henderson and Elefther-
iou, 2000). Point mutation of a conserved hydrophobic PEA-15 regulates ERK signaling, we used a yeast two-
hybrid screen to identify PEA-15-interactive proteins.residue (I15), predicted to be involved in NES function
(Henderson and Eleftheriou, 2000), resulted in a nuclear From a human brain cDNA library, 66 clones coding for
full-length ERK 1 and one clone coding for full-lengthaccumulation of PEA-15. Expression of this mutant
failed to exclude ERK from the nucleus (Figure 4D). In- ERK 2 were identified. Since ERK 1 clones differed in the
length of their 5-untranslated region, they representeddeed, this mutant appeared to increase nuclear ERK
relative to cells transfected with control vector DNA. independent clones; however, all were in frame with the
GAL4 activation domain of the vector, pACTII. All ERKThese results demonstrate that PEA-15 is excluded from
the nucleus due to an NES located at its N terminus. clones failed to interact with the unrelated protein, lamin,
or vector controls (Figure 5A). The binding of PEA-15Furthermore, cytoplasmic localization of PEA-15 is re-
quired for its capacity to sequester ERK in the cyto- was specific to ERK among the components of the ERK
MAP kinase pathway, since PEA-15 failed to interactplasm.
nucleus was less (open bars) or more (filled bars) stained for ERK than the cytoplasm were counted. Means  SEM of three independent
experiments are shown (n  800). Note that PEA-15 null cells manifest nuclear staining for ERK, even in 0.2% serum. In contrast, in wild-type
astrocytes, the ERK is predominantly cytoplasmic.
(E) PEA-15 null astrocytes were transfected with GFP-PEA-15 (PEA-15) or GFP alone (GFP) and stained for ERK. Note that in cells reconstituted
with GFP-PEA-15, ERK was no longer accumulated in the nucleus (arrows). In contrast, GFP expression had no effect on ERK localization
(arrows). The scale bar represents 10 m.
(F) Quantification of ERK localization upon expression of PEA-15 in null astrocytes. Cells in which the ERK staining was cytoplasmic (open
bars) or nuclear (filled bars) were enumerated for each condition (PEA-15, PEA-15 null cells reconstituted with GFP-PEA-15; GFP, cells
reconstituted with GFP alone; KO, nontransfected cells). Note that these cells were not serum starved. Means  SEM of five independent
experiments are shown (n  1600).
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Figure 5. PEA-15 Binds ERK
(A) PEA-15 interacts with ERK 1 and ERK 2
in yeast. Coexpression of PEA-15 and ERK 1
or ERK 2 allows growth on a selective medium
lacking histidine.
(B) PEA-15 does not interact with other mem-
bers of the MAPK cascade in yeast. Results
are representative of eight independent ex-
periments showing identical results for both
His prototrophy and 	-galactosidase activity.
The DED domain of PEA-15 alone and that of
a canonical DED-containing protein, FADD,
failed to interact with ERK 1 and ERK 2 in
yeast.
(C) PEA-15 binding to ERK is direct. Purified
recombinant ERK 2 was incubated with im-
mobilized His-tagged PEA-15, and binding
was assessed by Western blotting with an
anti-ERK antibody. Depicted is the anti-ERK
blot of proteins bound to the His-tagged PEA-
15 fusion protein (PEA-15), a His-tagged con-
trol protein (O), and the starting material
(Start).
(D) PEA-15 binds native ERK. CHO cells were
lysed and incubated with GST-PEA-15 fusion
protein-coated beads as described in the Ex-
perimental Procedures. Bound proteins were
immunoblotted with anti-ERK, -p38, or -JNK
antibodies. Depicted are Western blots of the
proteins bound to GST-PEA-15 (PEA-15),
GST alone (GST), and the starting cell lysate
(lysate). The lower panel is a Coomassie-
stained gel of the proteins bound to the gluta-
thione beads.
(E) CHO cells were cotransfected with vectors
encoding HA-PEA-15 and FLAG-tagged ERK
2. The lysates were separately immunopre-
cipitated by incubation with anti-haemagglu-
tinin (HA) antibody (PEA-15), anti-FLAG anti-
body (ERK), or control mouse IgG (IgG), as described in the Experimental Procedures. Note the presence of ERK 2 and PEA-15 in lysates
individually immunoprecipitated with anti-HA (PEA-15) or anti-FLAG (ERK) and their absence in cells immunoprecipitated with control
IgG (IgG).
with Ras, Raf1, or MEK1 (Figure 5B). Moreover, the asso- were recovered from both lysates (Figure 6A). Moreover,
Western blotting with an antibody specific to phosphor-ciation was due to a specific interaction with PEA-15,
ylated ERK 1 and 2 confirmed that both phosphorylatedsince no interaction could be detected with PEA-15’s
and unphosphorylated ERK 1 and 2 bound equally wellDED alone, or with another death effector domain pro-
to PEA-15 (Figure 6A). Furthermore, a kinase-inactive,tein, FADD (Figure 5B).
T192A, mutant of ERK 1 bound as well to PEA-15 as aIn order to confirm this interaction biochemically, a
wild-type ERK 1 (Figure 6B). Thus, the activation statepurified PEA-15-GST fusion was prepared, and cellular
of ERK does not influence its interaction with PEA-15.proteins that bound from a lysate of 3T3 cells were
Since PEA-15 has at least two serine phosphorylationanalyzed by Western blotting. PEA-15 specifically
sites, we asked whether ERK could phosphorylate PEA-bound native ERK 1/2 but not the related MAP kinases
15. Purified activated ERK efficiently phosphorylated thep38 or JNK (Figure 5D). Furthermore, purified recombi-
nuclear transcription factor Elk-1, but failed to phos-nant ERK 2 bound directly to immobilized PEA-15 (Fig-
phorylate PEA-15. In sharp contrast, PEA-15 was readilyure 5C). Finally, ERK and PEA-15 form a complex in
phosphorylated by PKC (Figure 6C). Thus, PEA-15 binds
mammalian cells, since they coimmunoprecipitated
to ERK irrespective of ERK’s activation state.
(Figure 5E), indicating in vivo association of the two
proteins. Thus, PEA-15 binds directly to ERK 1 and 2 PEA-15’s Capacity to Redirect Traffic in the MAP
but not to other kinases in the ERK pathway or to other Kinase Pathway Correlates with ERK Binding
MAP kinases. In order to explore the role of PEA-15 binding to ERK
To learn whether the interaction of ERK with PEA- on ERK function, we studied mutants of individual do-
15 was regulated by the activation state of ERK, we mains of PEA-15. We first analyzed the I15A mutant,
compared the capacity of PEA-15 to bind activated or which permitted ERK accumulation in the nucleus (Fig-
inactive ERK. Affinity chromatography was performed ure 4D). This mutation did not block ERK binding (Figure
on lysates of cells in which ERK 1 and 2 were activated 7A), indicating that PEA-15 capacity to redistribute ERK
by serum stimulation or blocked by the addition of the depended on its cytoplasmic localization. PEA-15 is com-
prised of an N-terminal death effector domain and aMEK inhibitor, U0126. Similar quantities of ERK 1 and 2
PEA-15 Sequesters ERK in the Cytoplasm
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for its ability to enforce cytoplasmic sequestration of
ERK and to impair ERK-dependent transcription and
cell proliferation.
Discussion
Precise regulation of the ERK MAP kinase pathway is
essential for the growth and survival of eukaryotic cells.
We found that PEA-15 blocks ERK phosphorylation of
nuclear but not cytoplasmic substrates and ERK-depen-
dent transcription. Furthermore, at physiological, but
high, abundance, PEA-15 limits the nuclear transloca-
tion of ERK and cell proliferation in astrocytes. PEA-15
does not impair the activation of ERK nor does it inhibit
ERK kinase activity. Instead, PEA-15 binds to ERK, re-
moving it from the nucleus in a manner dependent on
the PEA-15 nuclear export sequence (NES). In conse-
quence, PEA-15 modifies signaling in the MAP kinase
pathway by enforcing cytoplasmic localization of ERKs.
PEA-15 alters the output of ERK signaling without
blocking ERK activation. PEA-15 blocks MAP kinase
regulation of integrins without impairing ERK activation
(Ramos et al., 1998). We now report that PEA-15 blocks
the phosphorylation of ERK substrates in the nucleus
but not the cytoplasm with consequent inhibition of
ERK-dependent transcription. Moreover, we found that
physiological levels of PEA-15, expressed in cultured
astrocytes, can restrict ERK to the cytoplasm and block
ERK-dependent cFos transcription and cell proliferation
(Figures 3 and 7). PEA-15 is particularly enriched in ma-Figure 6. PEA-15 Is Not an ERK Substrate, and Binds Both Active
ture, nondividing astrocytes. During development of theand Inactive ERK
brain, PEA-15 expression begins relatively late at embry-(A) CHO cell lysates were prepared from cells that were cultured in
onic day 12 (E12; Danziger et al., 1995). From this stage,0.2% FCS for 18 hr in the presence of the MEK inhibitor U0126
(MEK Inh) to completely inactivate ERK. Alternatively, cells were PEA-15 levels continue to increase, reaching adult levels
stimulated with 20% FCS for 30 min (Serum). Cell lysates were by postnatal day 10 (P10). Moreover, the levels of PEA-
incubated with GST-PEA-15 or GST-coated Sepharose beads. The 15 in proliferating astrocytes are lower than in nonprolif-
bound ERK was visualized with anti-phospho-ERK antibody (upper
erating older astrocyte cultures (Danziger et al., 1995).panel) or anti-ERK 1 and 2 antibodies (lower panel). Note that PEA-15
Conversely, PEA-15 null mice exhibit markedly in-binds to both active phosphorylated ERK (upper panel) and inactive
creased cell proliferation in several lineages, includingnonphosphorylated ERK (lower panel).
(B) PEA-15 binds WT and a nonphosphorylatable mutant of ERK 1 lymphocytes and hepatocytes (S. Le Gouvello, F. Beu-
in vitro. WT and T192A ERK 1, radiolabeled with [35S]Met, were von, and H.C., unpublished data). Thus, increased PEA-
incubated with immobilized GST-PEA-15 or GST. Bound proteins 15 expression changes the biological consequences of
were detected with an Instant Imager.
ERK activation.(C) PEA-15 is not a substrate for ERK. Activated ERK was incubated
PEA-15 modifies ERK signaling by excluding ERKwith 1 g of GST-Elk-1 (307-428), GST-PEA-15, or GST in kinase
from the nucleus. High expression of PEA-15 resultedmedia containing [32P]ATP as described in the Experimental Proce-
dures. Radiolabeled proteins were fractionated by SDS-PAGE and in the export of ERK from the nucleus in astrocytes and
detected by autoradiography. In parallel experiments, we assayed in PEA-15-transfected cells. As noted above, PEA-15
the capacity of PKC to phosphorylate PEA-15 and a GST control. also inhibits cell proliferation. Thus, this observation
supports the hypothesis that ERK phosphorylation of
nuclear transcription factors is required for cell prolifera-C-terminal portion. Neither isolated domain bound ERK
well (Figure 7B). Furthermore, we previously found that a tion (Cobb, 1999). In addition, PEA-15 blocks the capac-
ity of activated Ras to suppress integrin activation, sug-mutation in a conserved Asp (D74A) in the death effector
domain of PEA-15 reduces its ability to reverse MAP gesting a possible role for nuclear localization of ERK
in this process (Ramos et al., 1998). Indeed, nuclearkinase suppression of integrin activation (Ramos et al.,
1998). That same mutation abrogated PEA-15 binding localization of ERK is important for many cellular pro-
cesses such as neurite extension (Robinson et al., 1998).to ERK 1/2 (Figure 7B). In contrast, Ala substitutions of
both phosphorylation sites (S104A and S116A) had no ERKs may be inactivated by exposure to phosphatases
such as MKP-1 in the nucleus. Thus, a rapid export fromeffect on ERK binding. The mutant of PEA-15 that lacked
the capacity to bind ERK also failed to inhibit the activa- the nucleus could contribute to the capacity of PEA-15
to potentiate ERK activation (Ramos et al., 2000). Hence,tion of Elk-1-dependent transcription (Figure 7C). Fur-
thermore, this mutant failed to block the serum-stimu- changes in the expression levels of PEA-15 can redefine
cellular responses to the ERK MAP kinase pathway bylated nuclear localization of ERK (Figures 7D and 7E),
and had no significant effect on cell proliferation (Figure excluding ERK from the nucleus.
PEA-15 binds ERK, and this interaction is correlated7F). Thus, the capacity of PEA-15 to bind ERK is required
Developmental Cell
246
Figure 7. Binding to ERK Is Required for PEA-15 Blockade of Transcription and Proliferation
(A) PEA-15 (I15A) mutant retains its ability to bind ERK. Cell lysates were incubated with the indicated GST-PEA-15 fusion protein-coated
beads as described in the Experimental Procedures. The upper panel is a Western blot of the bound protein and the lower panel is the
Coomassie-stained gel of the fusion protein-coated beads to confirm equal loading.
(B) CHO cells were lysed and incubated with GST-PEA-15 fusion protein-coated beads as described in the Experimental Procedures. C term
is the carboxyl-terminal half of PEA-15 (amino acids 79–130). DED is the death effector domain of PEA-15 alone (amino acids 1–80). D74A,
S104A, and S116A are full-length PEA-15 with the noted amino acid residue mutated to alanine. Finally, SSAA is full-length PEA-15 with both
serine 104 and 116 mutated to alanine. The upper panel is a Western blot of the bound protein and the lower panel is a Coomassie blue
staining of the proteins bound to glutathione beads.
(C) NIH 3T3 cells were transfected with 2 g of the indicated constructs. Cells were lysed after 48 hr and Elk-1 transcriptional activity was
measured in triplicate as described in the Experimental Procedures. The results shown are means  SEM and are representative of five
independent assays.
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with the inhibition of ERK nuclear localization and ERK- well to inactive ERK and phospho-ERK. Thus, we pro-
pose that PEA-15 binding to ERK results in the exportdependent proliferation. In yeast two-hybrid analysis,
PEA-15 bound to both ERK 1 and ERK 2. Moreover, of both active and inactive ERK to the cytoplasm. The
rapid export of active ERK from the nucleus provides anative cellular ERK 1 and 2 bound PEA-15, and the
proteins formed a complex in vivo. A PEA-15 mutant, mechanism whereby PEA-15 inhibits ERK nuclear func-
tion. However, astrocytes containing high levels ofD74A, failed to bind ERK and did not impair ERK nuclear
translocation or ERK-dependent transcription or cell PEA-15 can proliferate, albeit more slowly than PEA-15-
replete cells. Thus, it is likely that the capacity of PEA-15proliferation. The D74A mutation is in the last few amino
acids of the DED domain adjacent to the C-terminal half to bind ERK may be subject to regulation within cells.
It will be of interest to explore the mechanism of controlof the protein, and neither the C terminus nor the DED
is sufficient for ERK binding. This suggests that an ex- of this novel regulator of ERK signaling.
The results described here provide new insights intotended surface of PEA-15 involving both domains is
required for ERK binding. the pleiotropic effects of PEA-15. PEA-15 is overex-
pressed in patients with type II diabetes, and inhibitsPreviously identified ERK binding proteins fall into
three classes: (1) scaffolding proteins such as MP1 insulin-stimulated glucose transport and cell surface re-
cruitment of Glut-4 (Condorelli et al., 1998). While the(Schaeffer et al., 1998); (2) enzymes directly activating
or inactivating ERK, such as MEK (Lewis et al., 1998) role of ERK in glucose transport is uncertain, our data
suggest that PEA-15 overexpression could block glu-and the phosphatases MKP-3 (Camps et al., 1998; Muda
et al., 1996), PTP-SL, and STEP (Keyse, 2000); and (3) cose-stimulated ERK translocation (Khoo and Cobb,
1997). Furthermore, the 3-untranslated region (3 UTR)docking proteins associated with the microtubule cy-
toskeleton, such as MAP2 (Shafit-Zagardo and Kal- of PEA-15 is highly conserved, and is reported to be a
mammary oncogene called MAT1 (Bera et al., 1994).cheva, 1998). There is no obvious sequence similarity of
PEA-15 to other known ERK binding proteins. Moreover, Consequently, effects of MAT1 on PEA-15’s expression
levels might contribute to its transforming activity. Fi-PEA-15 does not appear to be a scaffold protein since
it did not bind other constituents of the ERK pathway. nally, PEA-15 contains a death effector domain, and can
regulate death receptor-dependent apoptosis (KitsbergFurthermore, PEA-15 lacks proline-directed ERK phos-
phorylation sites (Songyang et al., 1996) and it was not et al., 1999; Condorelli et al., 1999). Here, we report that
PEA-15 can also slow proliferation. Consequently, cellsa substrate for ERK in vitro. Finally, PEA-15 does not
contain a D domain, which is an ERK MAP kinase binding expressing high levels of PEA-15 would be rendered
quiescent and resistant to certain forms of apoptosis.sequence in proteins such as Elk-1 (Yang et al., 1998).
Hence, PEA-15 may define a new class of ERK binding These are characteristics of highly differentiated
astrocytes. Indeed, genetic deletion of PEA-15 resultsproteins.
PEA-15 contains an NES that is required for ERK local- in astrocytes that are more proliferative and more sus-
ceptible to TNF-induced apoptosis (Kitsberg et al.,ization to the cytosol, reminiscent of the role that the
MEK NES plays in the nuclear export of the ERK-MEK 1999). Thus, PEA-15 may help maintain populations of
differentiated quiescent cells.complex (Adachi et al., 2000). Leptomycin B, a specific
inhibitor of CRM1-mediated nuclear export, caused Thus far, the mechanisms involved in regulating each
of the three main MAP kinase pathways have been simi-PEA-15 accumulation in the nucleus. Furthermore, PEA-
15 contains a typical (Henderson and Eleftheriou, 2000) lar. These pathways involve cascades of kinases and
are regulated by phosphatases and scaffold proteins.NES, and mutation of this sequence results in its nuclear
localization. Nuclear localization of PEA-15 led to a loss It is likely, therefore, that other proteins that redirect
cellular localization of MAP kinases will be identified.of its capacity to restrict ERK to the cytoplasm, but did
not block its capacity to bind to ERK. Thus, PEA-15 PEA-15 was identified by an expression-cloning scheme
for proteins that blocked ERK signaling to integrins.relocalizes ERK to the cytoplasm via a nuclear export
mechanism. Such schemes will provide a facile means to identify
other proteins that can redirect traffic in MAP kinaseThe present results explain PEA-15’s capacity to se-
quester ERK in the cytoplasm. PEA-15 binds equally pathways.
(D) NIH 3T3 cells were transfected with wild-type PEA-15 or the D74A mutant (D74A) in fusion to GFP, and serum starved for 18 hr. Subsequently,
they were stimulated with 20% serum for 3 hr (serum) or maintained in 0.2% serum (starved) and then stained for ERK. Note that GFP-D74A
expression does not prevent ERK translocation to the nucleus upon serum stimulation (arrows), contrary to wild-type GFP-PEA-15 (arrows).
The scale bar represents 10 m. Quantitation of two independent experiments performed in triplicate showed that, upon serum stimulation,
ERK accumulated in the nucleus of more than 66  1% of the cells expressing GFP-D74A, whereas it was restricted to the cytoplasm of 77 
4% of cells transfected with wild-type GFP-PEA-15 (mean  SD).
(E) Reexpression of D74A in null astrocytes does not relocalize ERK to the cytoplasm. PEA-15 null astrocytes were transfected with GFP-
PEA-15 (PEA-15), GFP-D74A (D74A), or GFP alone (GFP). The percent of transfected cells exhibiting a nuclear staining for ERK is shown.
Means  SEM of three independent experiments
(F) Reexpression of PEA-15, but not PEA-15(D74A), in null astrocytes reduces cell cycle entry. PEA-15/ astrocytes were transfected with
GFP-PEA-15 (PEA15), GFP-PEA-15(D74A) (D74A), or GFP (GFP) and were grown in medium supplemented with 10% FCS for 18 hr. BrdU (10
M) was added and the cells were cultured for an additional 48 hr. Cells were then fixed and stained for BrdU as described in the Experimental
Procedures. The percent of transfected cells that are BrdU positive is shown (mean  SEM of three independent experiments). Levels of
expression of GFP, GFP-PEA-15, and GFP-D74A were similar as assayed by Western blotting of cell lysates 48 hr after transfection. Considering
the number of transfected cells, these levels were in a 2-fold range of magnitude as compared to endogenous levels of PEA-15 in WT
astrocytes. The asterisk indicate a statistically significant difference (p 
 0.05) as determined by t test.
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Experimental Procedures ERK Purification and Kinase Assays
Endogenous ERK was enriched from cytosolic extracts of NIH 3T3
cells by chromatography on Q-Sepharose fast flow (Pharmacia Bio-Cell Lines and Culture
NIH 3T3, CHO, 3T3-GFP, and 3T3-GFP-PEA-15 cell lines were cul- tech) as previously described (Chabre et al., 1995). Inactive ERK
was obtained from G0-arrested cells and activated ERK from cellstured in DMEM (Life Technologies), supplemented with 10% fetal
calf serum. The 3T3-GFP and 3T3-GFP-PEA-15 cell lines were ob- treated with 10% FCS for 10 min. Twenty l of these ERK-enriched
fractions (1 nM) were used for each kinase assay and performed intained by transfecting NIH 3T3 cells with the plasmids pEGFP-C1
(Clontech) and pEGFP-PEA-15 (Kitsberg et al., 1999), respectively. ERK kinase buffer (20 mM HEPES, 10 mM MgCl2, 20 mM para-
nitrophenylphosphate, 50 nM okadaic acid, 2.5 mM DTT, and 2.5Two clones resistant to G418 were selected for each construct.
Expression of GFP and GFP-PEA-15 was checked by fluorescence Ci [32P]ATP) in a final volume of 50 l for 15 min at 30C. One mU
of rat brain protein kinase C (Calbiochem) was used for each assayof living cells and Western blot analysis with anti-GFP and anti-PEA-
15 antibodies. Glial cultures were prepared as previously described in 50 l of PKC buffer (50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA,
10 mM MgCl2, 1.5 mM CaCl2, 1 mM DTT, 100 nM calyculin, 10(Araujo et al., 1993).
M ATP, 2.5 Ci [32P]ATP, and sonicated phosphatidylserine and
diacylglycerol) for 1 hr at 30C.cDNA Constructs and Antibodies
HA- and His-tagged PEA-15 were cloned into pcDNA3 (Invitrogen)
or pET28a (Novagen). Point mutants of PEA-15 were obtained using Transcription Assays and Northern Blot Analysis
the QuickChange site-directed mutagenesis kit (Stratagene). GST- Transcription assays were done using the Pathdetect in vivo signal
PEA-15 fusion proteins were constructed by subcloning full-length transduction pathway Elk-1 transreporting kit according to the man-
or mutant PEA-15 into the pGEX-4T1 vector (Amersham Pharmacia). ufacturer’s instructions (Stratagene). Briefly, NIH 3T3 cells were co-
D74A GFP-PEA-15 was obtained by subcloning the D74A mutant transfected with GAL4-Elk-1 (50 ng), GAL4-luciferase (100 ng), and
into the pEGFP-C1 vector. Anti-Elk-1, phospho-Elk-1, and phospho- PEA-15 (50 ng) or vector alone (50 ng). In some experiments, Raf-
ERK were purchased from New England Biolabs. Anti-ERK 1, -ERK CAAX (50 ng) was also transfected. GAL4-Elk-1 contains the DNA
2, -p38, and -JNK antibodies were obtained from Santa Cruz. binding domain of GAL4 fused to the transactivation domain of
Elk-1. GAL4-luciferase (100 ng) has the luciferase reporter gene
under the control of a synthetic promoter containing five tandemYeast Two-Hybrid
repeats of the yeast GAL4 binding sites. Cells were serum starvedThe ORF and the DED domains of human PEA-15 and FADD were
and stimulated with 20% serum as indicated. Elk-1 transcription wassubcloned into pLex or pGAD vectors. pLex-PEA-15 was used to
measured by the expression of active luciferase using the Promegascreen a human brain cDNA library (Clontech, MATCHMAKER) in
luciferase assay system according to the manufacturer’s instruc-S. cerevisiae strain L40. Yeast strains were grown and 	-galactosi-
tions.dase assays were performed as previously described (Breeden and
For Northern blot analysis, total RNA from primary cultureNasmyth, 1985). pLex-ERK 1 was created using one of the ERK 1
astrocytes was extracted using the RNeasy kit (Qiagen), separatedclones isolated in the screen. pLex-Lamin, pLex-RASWT, pLex-RAF,
on 1% agarose gels (Appligene), and transferred to Hybond-N mem-pGAD-RAF, and strain L40 are generous gifts from Dr. A. Vojtek and
branes (Pharmacia Amersham). Specific probes for human cFos andhave been described previously (Vojtek et al., 1993). pGAD-MEK1
GAPDH were synthesized and radiolabeled using the Prime It II kitwas kindly provided by Dr. L. Van Aelst (Van Aelst et al., 1993).
(Stratagene), and hybridized as previously described (Ausubel et
al., 1992). Specific binding was quantified on a Packard InstantImmunoprecipitations
Imager.CHO cells were cotransfected with vectors encoding HA-PEA-15
and FLAG-tagged ERK 2. Cells were washed with PBS buffer and
Immunocytochemistrylysed 36–40 hr after transfection. The lysate was centrifuged at
G0-arrested or serum-stimulated cells were washed twice with PBS12,000 rpm for 10 min, and cleared lysates (500 g protein) were
w/o Ca2 or Mg2, fixed with 4% paraformaldehyde, and permeabil-separately immunoprecipitated by incubation with 2 g anti-haemag-
ized with 0.2% Triton X-100 in PBS. Nonspecific sites were blockedglutinin (HA) antibody (PEA-15), anti-FLAG antibody (ERK), or con-
with 10% normal goat serum (NGS, Sigma) for 1 hr at room tempera-trol mouse IgG (IgG). Immune complexes were captured with protein
ture. Cells were then incubated overnight at 4C with the K-23 anti-A-Sepharose beads (10l) for 2 hr at 4C. After immunoprecipitation,
ERK 1 antibody (0.4 g/ml, Santa Cruz). After PBS washes, cellsthe beads were washed four times with lysis buffer, eluted with SDS
were incubated for 1 hr at room temperature with CY3-conjugatedsample buffer, resolved by SDS-PAGE under reducing conditions,
anti-rabbit antibody (0.4 g/ml, Amersham Pharmacia Biotech). Theand visualized by immunoblotting with a mixture of anti-FLAG and
nuclei were stained with Hoechst Dye 232 (Hoechst, 1g/ml in PBS)anti-HA antibodies.
for 5 min. Finally, cells were mounted under glass coverslips in
vectashield medium (Vector) and examined on a confocal micro-In Vitro Binding Assays
scope (Leica or Molecular Dynamics) or a Nikon EFD-3 microscopeUsing the plasmids pcDNA1-HA-ERK 1 wild-type and T192A-inac-
with appropriate filters.tive kinase, [35S]Met-radiolabeled proteins were synthesized in a
coupled in vitro transcription/translation reaction (TnT T7, Promega).
Radiolabeled proteins (2 l out of 50 l of translation reaction) were Proliferation Assays
[Methyl-3H]thymidine incorporation experiments were performed asincubated with 1g of GST-PEA-15 or 1g of GST (negative control)
adsorbed on glutathione-Sepharose beads as previously described previously described (Pebay et al., 1999). For cell number quantita-
tion, primary culture astrocytes were trypsinized, counted, and re-(Camps et al., 1998). Proteins were resolved by SDS-PAGE, and
radiolabeled ERK 1 was detected in a Packard Instant Imager. For plated at the indicated concentration for both genotypes on 35 mm
plates coated with polyornithine. Cells were grown for the indicateddirect interactions, 5 g of recombinant ERK 2 (New England Bio-
labs) was incubated under the same conditions with 2 g of His- time in medium supplemented with 10% FCS. Cells were then
washed with PBS, trypsinized, and counted with a hemocytometer.tagged PEA-15 or His tag alone immobilized on Sepharose beads.
Alternatively, NIH 3T3 or CHO cells were stimulated with serum or For 5-bromo-2-deoxyuridine (BrdU) incorporation experiments, pri-
mary astrocytes were replated on 35 mm polyornithine-coatedtransfected as indicated, and then lysed in MLB buffer (25 mM
HEPES, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, plates and transfected the following day with the indicated con-
structs. Eighteen hr after transfection, cells were stimulated with10% glycerol, 10 mM MgCl2, and 1 mM EDTA). The lysates (500
g) were then mixed with 50 l of Sepharose-bound GST-PEA-15 10% FCS for 48 hr in the presence of 10 M BrdU (Sigma). After
fixation, the chromatin was rendered accessible by a 20 min treat-(approximately 2 mg) or the indicated mutants for 2 hr at 4C. Beads
were washed with MLB, and the PEA-15 protein complex was re- ment with 2N HCl, followed by a 10 min neutralizing step with 0.1
M borate (pH 8.5). Incorporated BrdU was detected by incubatingleased by thrombin (1 unit) cleavage of the PEA-15 away from the
fused GST. The complex was then visualized by PAGE and Western the cells for 2 hr with an anti-BrdU antibody (0.1 g/ml, Becton
Dickinson) in the presence of 3% NGS and 0.8% Triton X-100, andblotting.
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then for 1 hr with a CY3-conjugated anti-mouse antibody (0.4 g/ Chneiweiss, H. (1995). Cellular expression, developmental regula-
tion, and phylogenic conservation of PEA-15, the astrocytic majorml, Amersham Pharmacia Biotech).
phosphoprotein and protein kinase C substrate. J. Neurochem. 64,
1016–1025.Acknowledgments
Estelles, A., Yokoyama, M., Nothias, F., Vincent, J.D., Glowinski, J.,
The authors gratefully acknowledge Dr. G. Page`s (CNRS, Nice) for Vernier, P., and Chneiweiss, H. (1996). The major astrocytic phos-
pcDNA1-HA-ERK 1 and T192A pcDNA1-HA-ERK 1 constructs, Dr. phoprotein PEA-15 is encoded by two mRNAs conserved on their
R. Hipskind (CNRS, Montpellier) for GST-Elk-1 (307-428), Dr. A.S. full length in mouse and human. J. Biol. Chem. 271, 14800–14806.
Lebre´ (INSERM, Paris) for the brain cDNA library, Dr. Andre´ Sobel Fornerod, M., Ohno, M., Yoshida, M., and Mattaj, I.W. (1997). CRM1
(INSERM, Paris) for antibodies against stathmin and phosphostath- is an export receptor for leucine-rich nuclear export signals. Cell
min, and Drs. J.-A. Girault (INSERM, Paris) and Ph. Lenormand 90, 1051–1060.
(CNRS, Nice) for leptomycin B. We also thank Dr. B. Alinquant (Ecole
Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Ya-Normale Supe´rieure, Paris) and Dr. D. Alfandari (Universite´ Paris VI)
nagida, M., and Nishida, E. (1997). CRM1 is responsible for intracel-for confocal facilities, N. Choudey, B. Guibert, and E. Etienne for
lular transport mediated by the nuclear export signal. Nature 390,technical assistance, and Pr. Jacques Glowinski for constant help
308–311.and support. This work was supported by funds from the Institut
Henderson, B.R., and Eleftheriou, A. (2000). A comparison of theNational de la Sante´ et de la Recherche Me´dicale (INSERM), the
activity, sequence specificity, and CRM1-dependence of differentAssociation pour la Recherche contre le Cancer (ARC, grant #9966),
nuclear export signals. Exp. Cell Res. 256, 213–224.the Fondation pour la Recherche Me´dicale (FRM), the National Insti-
tutes of Health (NIH), and the Leukemia Society of America and the Hochholdinger, F., Baier, G., Nogalo, A., Bauer, B., Grunicke, H.H.,
Cancer Research Fund, under Interagency Agreement #97-12013 and Uberall, F. (1999). Novel membrane-targeted ERK1 and ERK2
(University of California contract #98-00924V) with the Department chimeras which act as dominant negative, isotype-specific mitogen-
of Health Services, Cancer Research Program. activated protein kinase inhibitors of Ras-Raf-mediated transcrip-
tional activation of cFos in NIH 3T3 cells. Mol. Cell. Biol. 19, 8052–
8065.Received July 10, 2000; revised July 11, 2001.
Hughes, P.E., Renshaw, M.W., Pfaff, M., Forsyth, J., Keivens, V.M.,
References Schwartz, M.A., and Ginsberg, M.H. (1997). Suppression of integrin
activation: a novel function of a Ras/Raf-initiated MAP kinase path-
way. Cell 88, 521–530.Adachi, M., Fukuda, M., and Nishida, E. (2000). Nuclear export of
MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent Keyse, S.M. (2000). Protein phosphatases and the regulation of mito-
active transport mechanism. J. Cell. Biol. 148, 849–856. gen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12,
186–192.Araujo, H., Danziger, N., Cordier, J., Glowinski, J., and Chneiweiss,
H. (1993). Characterization of PEA-15, a major substrate for protein Khoo, S., and Cobb, M.H. (1997). Activation of mitogen-activating
kinase C in astrocytes. J. Biol. Chem. 268, 5911–5920. protein kinase by glucose is not required for insulin secretion. Proc.
Natl. Acad. Sci. USA 94, 5599–5604.Ashkenazi, A., and Dixit, V.M. (1998). Death receptors: signaling and
modulation. Science 281, 1305–1308. Kitsberg, D., Formstecher, E., Fauquet, M., Kubes, M., Cordier, J.,
Canton, B., Pan, G., Rolli, M., Glowinski, J., and Chneiweiss, H.Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G.,
Smith, J.A., and Struhl, K. (1992). Short Protocols in Molecular Biol- (1999). Knock-out of the neural death-effector-domain protein PEA-
15 demonstrates that its expression protects astrocytes from TNF-ogy (New York: Greene and Wiley).
induced apoptosis. J. Neurosci. 19, 8244–8251.Bera, T.K., Guzman, R.C., Miyamoto, S., Panda, D.K., Sasaki, M.,
Hanyu, K., Enami, J., and Nandi, S. (1994). Identification of a mam- Kubes, M., Cordier, J., Glowinski, J., Girault, J.A., and Chneiweiss,
H. (1998). Endothelin induces a calcium-dependent phosphorylationmary transforming gene (MAT1) associated with mouse mammary
carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 9789–9793. of PEA-15 in intact astrocytes: identification of Ser104 and Ser116
phosphorylated, respectively, by protein kinase C and calcium/cal-Breeden, L., and Nasmyth, K. (1985). Regulation of the yeast HO
modulin kinase II in vitro. J. Neurochem. 71, 1307–1314.gene. Cold Spring Harb. Symp. Quant. Biol. 50, 643–650.
Kudo, N., Wolff, B., Sekimoto, T., Schreiner, E.P., Yoneda, Y., Yanag-Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S., and Pouys-
ida, M., Horinouchi, S., and Yoshida, M. (1998). Leptomycin B inhibi-segur, J. (1999). Nuclear translocation of p42/p44 mitogen-activated
tion of signal-mediated nuclear export by direct binding to CRM1.protein kinase is required for growth factor-induced gene expression
Exp. Cell Res. 242, 540–547.and cell cycle entry. EMBO J. 18, 664–674.
Lewis, T.S., Shapiro, P.S., and Ahn, N.G. (1998). Signal transductionCamps, M., Nichols, A., Gillieron, C., Antonsson, B., Muda, M., Cha-
through MAP kinase cascades. Adv. Cancer Res. 74, 49–139.bert, C., Boschert, U., and Arkinstall, S. (1998). Catalytic activation of
the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Muda, M., Boschert, U., Dickinson, R., Martinou, J.C., Martinou, I.,
Camps, M., Schlegel, W., and Arkinstall, S. (1996). MKP-3, a novelScience 280, 1262–1265.
cytosolic protein-tyrosine phosphatase that exemplifies a new classChabre, O., Cornillon, F., Bottari, S.P., Chambaz, E.M., and Vilgrain,
of mitogen-activated protein kinase phosphatase. J. Biol. Chem.I. (1995). Hormonal regulation of mitogen-activated protein kinase
271, 4319–4326.activity in bovine adrenocortical cells: cross-talk between phospho-
inositides, adenosine 3,5-monophosphate, and tyrosine kinase re- Pebay, A., Torrens, Y., Toutant, M., Cordier, J., Glowinski, J., and
Tence, M. (1999). Pleiotropic effects of lysophosphatidic acid onceptor pathways. Endocrinology 136, 956–964.
striatal astrocytes. Glia 28, 25–33.Cobb, M.H. (1999). MAP kinase pathways. Prog. Biophys. Mol. Biol.
71, 479–500. Ramos, J.W., Kojima, T.K., Hughes, P.E., Fenczik, C.A., and Gins-
berg, M.H. (1998). The death effector domain of PEA-15 is involved inCondorelli, G., Vigliotta, G., Iavarone, C., Caruso, M., Tocchetti, C.G.,
its regulation of integrin activation. J. Biol. Chem. 273, 33897–33900.Andreozzi, F., Cafieri, A., Tecce, M.F., Formisano, P., Beguinot, L.,
and Beguinot, F. (1998). PED/PEA-15 gene controls glucose trans- Ramos, J.W., Hughes, P.E., Renshaw, M.W., Schwartz, M.A.,
Formstecher, E., Chneiweiss, H., and Ginsberg, M.H. (2000). Deathport and is overexpressed in type 2 diabetes mellitus. EMBO J. 17,
3858–3866. effector domain protein PEA-15 potentiates ras activation of extra-
cellular signal receptor-activated kinase by an adhesion-indepen-Condorelli, G., Vigliotta, G., Cafieri, A., Trencia, A., Andalo, P., Or-
dent mechanism. Mol. Biol. Cell 11, 2863–2872.iente, F., Miele, C., Caruso, M., Formisano, P., and Beguinot, F.
(1999). PED/PEA-15: an anti-apoptotic molecule that regulates FAS/ Robinson, M.J., and Cobb, M.H. (1997). Mitogen-activated protein
kinase pathways. Curr. Opin. Cell Biol. 9, 180–186.TNFR1-induced apoptosis. Oncogene 18, 4409–4415.
Danziger, N., Yokoyama, M., Jay, T., Cordier, J., Glowinski, J., and Robinson, M.J., Stippec, S.A., Goldsmith, E., White, M.A., and Cobb,
Developmental Cell
250
M.H. (1998). A constitutively active and nuclear form of the MAP
kinase ERK2 is sufficient for neurite outgrowth and cell transforma-
tion. Curr. Biol. 8, 1141–1150.
Schaeffer, H.J., and Weber, M.J. (1999). Mitogen-activated protein
kinases: specific messages from ubiquitous messengers. Mol. Cell.
Biol. 19, 2435–2444.
Schaeffer, H.J., Catling, A.D., Eblen, S.T., Collier, L.S., Krauss, A.,
and Weber, M.J. (1998). MP1: a MEK binding partner that enhances
enzymatic activation of the MAP kinase cascade. Science 281,
1668–1671.
Schwartz, M.A., Schaller, M.D., and Ginsberg, M.H. (1995). Integrins:
emerging paradigms of signal transduction. Annu. Rev. Cell Dev.
Biol. 11, 549–599.
Shafit-Zagardo, B., and Kalcheva, N. (1998). Making sense of the
multiple MAP-2 transcripts and their role in the neuron. Mol. Neuro-
biol. 16, 149–162.
Songyang, Z., Lu, K.P., Kwon, Y.T., Tsai, L.H., Filhol, O., Cochet, C.,
Brickey, D.A., Soderling, T.R., Bartleson, C., Graves, D.J., et al.
(1996). A structural basis for substrate specificities of protein Ser/
Thr kinases: primary sequence preference of casein kinases I and
II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II,
CDK5, and Erk1. Mol. Cell. Biol. 16, 6486–6493.
Sperling, R., Sperling, J., Levine, A.D., Spann, P., Stark, G.R., and
Kornberg, R.D. (1985). Abundant nuclear ribonucleoprotein form of
CAD RNA. Mol. Cell. Biol. 5, 569–575.
Van Aelst, L., Barr, M., Marcus, S., Polverino, A., and Wigler, M.
(1993). Complex formation between RAS and RAF and other protein
kinases. Proc. Natl. Acad. Sci. USA 90, 6213–6217.
Vojtek, A.B., Hollenberg, S.M., and Cooper, J.A. (1993). Mammalian
Ras interacts directly with the serine/threonine kinase Raf. Cell 74,
205–214.
Waskiewicz, A.J., and Cooper, J.A. (1995). Mitogen and stress re-
sponse pathways: MAP kinase cascades and phosphatase regula-
tion in mammals and yeast. Curr. Opin. Cell Biol. 7, 798–805.
Wolff, B., Sanglier, J.J., and Wang, Y. (1997). Leptomycin B is an
inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translo-
cation of the human immunodeficiency virus type 1 (HIV-1) Rev
protein and Rev-dependent mRNA. Chem. Biol. 4, 139–147.
Yang, S.H., Whitmarsh, A.J., Davis, R.J., and Sharrocks, A.D. (1998).
Differential targeting of MAP kinases to the ETS-domain transcrip-
tion factor Elk-1. EMBO J. 17, 1740–1749.
